| Species |
Human |
| Protein Construction |
| His |
CDCP1 ATF (30-368) (Phe30-Arg368)
Accession # Q9H5V8-1 |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized CDCP1 ATF (30-368), His, Human at 2μg/ml (100μl/well) on the plate can bind AntiCDCP1 Antibody, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
39.03 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 55-70 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Tumor metastasis depends on the dynamic regulation of cell adhesion through β1-integrin. The Cub-Domain Containing Protein-1, CDCP1, is a transmembrane glycoprotein which regulates cell adhesion. Overexpression and loss of CDCP1 have been observed in the same cancer types to promote metastatic progression. |
| Synonyms |
CDCP1; CD318; SIMA135; TRASK; UNQ2486; PRO5773 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
